GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.8616
-0.0834 (-8.83%)
At close: Sep 8, 2025, 4:00 PM
0.7785
-0.0831 (-9.64%)
After-hours: Sep 8, 2025, 7:59 PM EDT

GT Biopharma Statistics

Total Valuation

GT Biopharma has a market cap or net worth of $3.07 million. The enterprise value is -$2.16 million.

Market Cap3.07M
Enterprise Value -2.16M

Important Dates

The last earnings date was Thursday, August 14, 2025, after market close.

Earnings Date Aug 14, 2025
Ex-Dividend Date n/a

Share Statistics

GT Biopharma has 3.56 million shares outstanding. The number of shares has increased by 64.62% in one year.

Current Share Class 3.56M
Shares Outstanding 3.56M
Shares Change (YoY) +64.62%
Shares Change (QoQ) +18.19%
Owned by Insiders (%) 10.99%
Owned by Institutions (%) 9.57%
Float 2.18M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 0.99
P/TBV Ratio 1.07
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.09

Current Ratio 3.09
Quick Ratio 2.27
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -181.99% and return on invested capital (ROIC) is -130.90%.

Return on Equity (ROE) -181.99%
Return on Assets (ROA) -82.45%
Return on Invested Capital (ROIC) -130.90%
Return on Capital Employed (ROCE) -224.46%
Revenue Per Employee n/a
Profits Per Employee -$9.48M
Employee Count1
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -55.82% in the last 52 weeks. The beta is 1.37, so GT Biopharma's price volatility has been higher than the market average.

Beta (5Y) 1.37
52-Week Price Change -55.82%
50-Day Moving Average 1.81
200-Day Moving Average 2.34
Relative Strength Index (RSI) 24.38
Average Volume (20 Days) 334,144

Short Selling Information

The latest short interest is 260,999, so 7.34% of the outstanding shares have been sold short.

Short Interest 260,999
Short Previous Month 282,275
Short % of Shares Out 7.34%
Short % of Float 11.95%
Short Ratio (days to cover) 3.33

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -10.81M
Pretax Income -9.64M
Net Income -9.48M
EBITDA n/a
EBIT -10.81M
Earnings Per Share (EPS) -$3.94
Full Income Statement

Balance Sheet

The company has $5.23 million in cash and n/a in debt, giving a net cash position of $5.23 million or $1.47 per share.

Cash & Cash Equivalents 5.23M
Total Debt n/a
Net Cash 5.23M
Net Cash Per Share $1.47
Equity (Book Value) 4.82M
Book Value Per Share 0.87
Working Capital 4.82M
Full Balance Sheet

Cash Flow

Operating Cash Flow -10.42M
Capital Expenditures n/a
Free Cash Flow -10.42M
FCF Per Share -$2.93
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

GT Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -64.62%
Shareholder Yield -64.62%
Earnings Yield -309.28%
FCF Yield -339.98%

Analyst Forecast

The average price target for GT Biopharma is $11.00, which is 1,176.70% higher than the current price. The consensus rating is "Strong Buy".

Price Target $11.00
Price Target Difference 1,176.70%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.

Last Split Date Feb 5, 2024
Split Type Reverse
Split Ratio 1:30

Scores

Altman Z-Score n/a
Piotroski F-Score 1